Relief of obstruction is noted immediately in the majority of appropriately selected patients. Clinical success is defined as a 50% or more reduction in peak gradient across the outflow tract, predicting continued improvement in gradient and cardiac remodeling over the ensuing 1 to 2 years. Over 90% of patients experience a successful procedure, with improvement in outflow tract gradient and mitral regurgitation. Patients typically report progressive reduction in symptoms, including improved shortness of breath, lightheadedness and chest pain. Serial echocardiograms are routinely obtained to follow the cardiac remodeling over time, and document reduction in outflow tract gradient. Although<unk>  improves symptoms associated with HCM, it does not decrease the risk of sudden cardiac death (SCM) and may possibly increase it due to theoretical risk for arrhythmogenic scarring. When compared to surgical myectomy, similar outcomes are noted out to approximately 10 years. However, a prospective, randomized trial has not been performed. Despite initial concerns regarding long-term arrhythmic potential after<unk> , the risk appears to be no worse than for surgical myectomy. It is important to note that patients who fail to respond to<unk>  may still be candidates for surgical myectomy, and vice versa. Which patients are best served by surgical myectomy,<unk> , or medical therapy is an important topic and one which is intensely debated in medical scientific circles.
Alcohol septal ablation
Valvulotomy
Catheter ablation
Transmyocardial revascularization
Cardiomyoplasty
Cardiac resynchronization therapy
Aortic valvuloplasty
Percutaneous pulmonary valve implantation